Oral lichenoid drug reactions induced by secukinumab injection: a case report

Published on Mar. 04, 2024Total Views: 1709 times Total Downloads: 2621 times Download Mobile

Author: LI Dandan ¹ WAN Zixin ²  WANG Jianli ¹

Affiliation: 1. Department of Pharmacy, State Key Laboratory of Oral Diseases/National Center for Stomatology/National Clinical Research Center for Oral Diseases/West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China 2. Department of Oral Pathology, State Key Laboratory of Oral Diseases/National Center for Stomatology/National Clinical Research Center for Oral Diseases/West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Keywords: Secukinumab Oral lichenoid drug reactions Adverse drug reactions

DOI: 10.12173/j.issn.1005-0698.202311027

Reference: LI Dandan, WAN Zixin, WANG Jianli.Oral lichenoid drug reactions induced by secukinumab injection: a case report[J].Yaowu Liuxingbingxue Zazhi,2024, 33(4):461-465.DOI: 10.12173/j.issn.1005-0698.202311027.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 57-year-old female patient was treated with secukinumab injection for psoriasis. After the eighth administration, large area of reticular streaks with hyperemia and erosion appeared on the dorsum of the tongue and left buccal mucosa, which improved after three weeks of corticosteroids treatment. The symptoms worsened after re-administration and a diagnosis of an oral lichenoid drug reaction (OLDR) was made, which improved after eight weeks of corticosteroids treatment. There was no recurrence four months after secukinumab injection withdrawal. By correlation analysis, the causal relationship between OLDR and Secukinumab injection was evaluated as "be sure", which had not been reported in China. The clinical manifestations of oral lichenoid drug reactions were unilateral buccal mucosa with hyperemia and erosion. Discontinuation of suspected drugs and topical application of corticosteroids were the most effective treatments.

Full-text

Please download the PDF version to read the full text: download

References

1.Teoh L, Moses G, Mccullough MJ. A review and guide to drug associated oral adverse effects-oral mucosal and lichenoid reactings. part 2[J]. J Oral Pathol Med, 2019, 48(7): 637-646. DOI: 10.1111/jop.12910.　

2.陈煜鑫, 周瑜, 陈谦明. 口腔苔藓样病变的研究进展 [J]. 国际口腔医学杂志, 2020, 47(1): 51-57. [Chen YX, Zhou Y, Chen QM. Research progress on oral lichenois lesions[J]. International Journal of Stomatology, 2020, 47(1): 51-57.] DOI: 10.7518/gjkq.2020030.

3.刘晓明. 国内外最新银屑病诊疗指南解读——疾病严重程度评估及生物制剂治疗[J]. 皮肤性病诊疗学杂志, 2023, 30(1): 1-5. [Liu XM. Interpretation of the latest guidelines for the diagnosis and the treatment of psoriasis at home and abroad:the assessment of disease severity and the treatment with biological agents[J]. Journal of Diagnosis and Therapy on Dermato-venereology, 2023, 30(1): 1-5.]DOI: 10.3969/j.issn.1674-8468.2023.01.001.

4.卢锐, 周刚. 口腔苔藓样病变的概念、分类及临床病理特征[J]. 口腔医学研究, 2021, 37(12): 1063-1068. [Lu R, Zhou G. Conception,classification,and clinicopathologic features of oral lichenoid lesions[J]. Journal of Oral Science Research, 2021, 37(12): 1063-1068.] DOI: 10.13701/j.cnki.kqyxyj.2021.12.001.

5.陈谦明, 华红, 曾昕, 主编. 口腔黏膜病学, 第5版[M]. 北京:人民卫生出版社, 2020: 90-91.

6.原国家卫生部. 药品不良反应报告和监测管理办法(卫生部令第81号)[EB/OL]. (2011-05-04) [2019-04-21]. http://www.nhc.gov.cn/fzs/s3576/201105/ac4ab24c135a43379f2af1694457f65e.shtml.

7.Thompson JM, Cohen LM, Yang CS, et al. Severe, ulcerative, lichenoid mucositis associated with secukinumab[J]. JAAD Case Rep, 2016, 2(5): 384-386. DOI: 10.1016/j.jdcr.2016.07.009.

8.Komori T, Honda T, Endo Y, et al. Oral lichen planus associated with candidiasis during secukinumab treatment[J]. J Dermatol, 2017, 44(4): e60-e61. DOI: 10.1111/1346-8138.13637.

9.Capusan TM, Herrero-Moyano M, Martínez-Mera CR, et al. Oral lichenoid reaction in a psoriatic patient treated with secukinumab: adrug-related rather than a class-related adverse event?[J]. JAAD Case Rep, 2018, 4: 521-523. DOI: 10.1016/j.jdcr.2018.04.015.

10.Farah CS. Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy[J]. Aust Dent J, 2021, 66(3): 340-345. DOI: 10.1111/adj.12833.

11.Fujita Y, Sugai T, Maya Y, et al. Secukinumab-induced oral lichen planus in a psoriatic arthritis patient ameliorated after a switch to risankizumab[J]. J Dermatol, 2023, 50: 824-827. DOI: 10.1111/1346-8138.16719.

12.Sharma AM, Uetrecht J. Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions[J]. Drug Metab Rev, 2014, 46(1): 1-18. DOI: 10.3109/03602532.2013.848214.

13.Khammissa RAG, Chandran R, Masilana A, et al. Adverse immunologically mediated oral mucosal reactions to systemic medication: lichenoid tissue reaction/interface dermatitis-stomatitis, autoimmune vesiculobullous disease, and IgE-dependent and immune complex reactions[J]. J Immunol Res, 2018, 2018: 7645465. DOI: 10.1155/2018/7645465.

14.杨晓姣, 周瑾, 董艳, 等. IL-17A抑制剂司库奇尤单抗和依奇珠单抗致不良反应文献分析[J].中国新药杂志, 2022, 31(10): 1027-1032. [Yang XJ, Zhou J, Dong Y. Literature analysis of adverse drug reactions induced by IL-17A inhibitors:secukinumab and ixekizumab[J]. Chinese Journal of New Drugs, 2022, 31(10): 1027-1032.] DOI: 10.3969/j.issn.1003-3734.2022.10.016.

15.冀召帅, 毛乾泰, 艾超. 司库奇尤单抗不良反应文献分析[J]. 中南药学, 2022, 20(4): 955-960. [Ji SS, Mao QT, Ai C. Literature analysis of adverse drug reactions induced by secukinumab[J]. Central South Pharmacy, 2022, 20(4): 955-960.] DOI: 10.7539/j.issn.1672-2981.2022.04.038.

16.Thomson PJ, Goodson ML, Smith DR. Potentially malignant disorders revisited-the lichenoid lesion/prolifer -ative verrucous leukoplakia conundrum[J]. J Oral Pathol Med, 2018, 47(6): 557-565. DOI: 10.1111/jop.12716.